Advanced search
Publication Cover
Future Virology Volume 8, 2013 - Issue 9
Submit an article Journal homepage
75
Views
0
CrossRef citations to date
0
Altmetric
Review

Orthopoxvirus Inhibitors that are Active in Animal Models: An Update from 2008 to 2012

Donald F SmeeInstitute for Antiviral Research, Department of Animal, Dairy & Veterinary Sciences, Utah State University, Logan, UT, 84322-5600, USA. Tel.: +1 435 797 2897 Fax: +1 435 797 [email protected]View further author information
Pages 891-901 | Published online: 27 Aug 2013

References

  • Cleri DJ , PorwancherRB, RickettiAJ, Ramos-BonnerLS, VernaleoJR. Smallpox as a bioterrorist weapon: myth or menace? Infect. Dis. Cin. North Am.20(2) , 329–357 (2006).
  • Anderson PD , BokorG. Bioterrorism: pathogens as weapons. J. Pharm. Practice25(5) , 521–529 (2012).
  • Russell PK . Project BioShield: what it is, why it is needed, and its accomplishments so far. Clin. Infect. Dis.45(Suppl. 1) , S68–S72 (2007).
  • Russell PK , GronvallGK. U.S. medical countermeasure development since 2001: a long way yet to go. Biosecur. Bioterror.10(1) , 66–76 (2012).
  • Bray M . Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res.58(2) , 101–114 (2003).
  • Bray M , WrightME. Progressive vaccinia. Clin. Infect. Dis.36(6) , 766–774 (2003).
  • Reed JL , ScottDE, BrayM. Eczema vaccinatum. Clin. Infect. Dis.54(6) , 832–840 (2012).
  • Smee DF , SidwellRW. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res.57(1–2) , 41–52 (2003).
  • Smee DF . Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir. Chem. Chemother.19(3) , 115–124 (2008).
  • Duraffour S , MatthysP, van den Oord JJ et al. Study of camelpox virus pathogenesis in athymic nude mice. PLoS ONE6(6) , e21561 (2011).
  • Anderson MG , FrenkelLD, HomannS, GuffeyJ. A case of severe monkeypox virus disease in an American child: emerging infections and changing professional values. Ped. Infect. Dis. J.22(12) , 1093–1096 (2003).
  • Smith AL , St Claire M, Yellayi S et al. Intrabronchial inoculation of cynomolgus macaques with cowpox virus. J. Gen. Virol.93(Pt 1) , 159–164 (2012).
  • Goff AJ , ChapmanJ, FosterC et al. A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. J. Virol. 85(10) , 4898–4909 (2011).
  • Barnewall RE , FisherDA, RobertsonAB, ValesPA, KnostmanKA, BiggerJE. Inhalational monkeypox virus infection in cynomolgus macaques. Front. Cell Infect. Microbiol.2 , 117 (2012).
  • Goff A , MuckerE, RaymondJ et al. Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein. Arch. Virol. 156(10) , 1877–1881 (2011).
  • Parker S , BullerRM. A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012. Future Virol.8(2) , 129–157 (2013).
  • Jordan R , HrubyD. Smallpox antiviral drug development: satisfying the animal efficacy rule. Expert Rev. Anti Infect. Ther.4(2) , 277–289 (2006).
  • Duraffour S , AndreiG, TopalisD et al. Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus. J. Virol. 86(13) , 7310–7325 (2012).
  • Yang G , PevearDC, DaviesMH et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79(20) , 13139–13149 (2005).
  • Jordan R , LeedsJM, TyavanagimattS, HrubyDE. Development of ST-246® for treatment of poxvirus infections. Viruses2(11) , 2409–2435 (2010).
  • Vora S , DamonI, FulginitiV et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 46(10) , 1555–1561 (2008).
  • Wertheimer ER , OliveDS, BrundageJF, ClarkLL. Contact transmission of vaccinia virus from smallpox vaccinees in the United States, 2003–2011. Vaccine30(6) , 985–988 (2012).
  • Lederman ER , DavidsonW, GroffHL et al. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J. Infect. Dis. 206(9) , 1372–1385 (2012).
  • Erickson C , DriscollM, GaspariA. Efficacy of intravenous cidofovir in the treatment of giant molluscum contagiosum in a patient with human immunodeficiency virus. Arch. Dermatol.147(6) , 652–654 (2011).
  • Cohen JI , DavilaW, AliMA et al. Detection of molluscum contagiosum virus (MCV) DNA in the plasma of an immunocompromised patient and possible reduction of MCV DNA with CMX-001. J. Infect. Dis. 205(5) , 794–797 (2012).
  • Fisher RW , ReedJL, SnoyPJ et al. Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin. Clin. Vaccine Immunol. 18(1) , 67–74 (2011).
  • Neyts J , De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol.41(3) , 242–246 (1993).
  • Ciesla SL , TrahanJ, WanWB et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 59(3) , 163–171 (2003).
  • Lanier R , TrostL, TippinT et al. Development of CMX001 for the treatment of poxvirus infections. Viruses 2(12) , 2740–2762 (2010).
  • Painter W , RobertsonA, TrostLC, GodkinS, LampertB, PainterG. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob. Agents Chemother.56(5) , 2726–2734 (2012).
  • Jordan R , GoffA, FrimmA et al. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53(5) , 1817–1822 (2009).
  • Kuroda K , FukudaT, OkumuraK et al. Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells. Anticancer Drugs 24(8) , 826–834 (2013).
  • Miller RL , MengTC, TomaiMA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect.21(2) , 69–87 (2008).
  • Overby LR , DuffRG, MaoJC. Antiviral potential of phosphonoacetic acid. Ann. NY Acad. Sci.284 , 310–320 (1977).
  • Reeves PM , BommariusB, LebeisS et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 11(7) , 731–739 (2005).
  • Deng L , DaiP, CiroA, SmeeDF, DjaballahH, ShumanS. Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J. Virol.81(24) , 13392–13402 (2007).
  • Kern ER , PrichardMN, QuenelleDC et al. Activities of certain 5-substituted 4´-thiopyrimidine nucleosides against orthopoxvirus infections. Antimicrob. Agents Chemother. 53(2) , 572–579 (2009).
  • Neyts J , VerbekenE, De Clercq E. Effect of 5-iodo-2´-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother.46(9) , 2842–2847 (2002).
  • Smee DF , SidwellRW. Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2´-fluoro-arabinofuranosyl nucleosides. Nucleosides Nucleotides Nucleic Acids23(1–2) , 375–383 (2004).
  • Rus F , MorlockK, SilvermanN, PhamN, KotwalGJ, MarshallWL. Characterization of poxvirus-encoded proteins that regulate innate immune signaling pathways. Methods Mol. Biol.890 , 273–288 (2012).
  • Smee DF , BaileyKW, WongMH, WanderseeMK, SidwellRW. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis.190(6) , 1132–1139 (2004).
  • Quenelle DC , PrichardMN, KeithKA et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 51(11) , 4118–4124 (2007).
  • Reynolds MG , DamonIK. Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol.20(2) , 80–87 (2012).
  • Parker S , ChenNG, FosterS et al. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox – an animal model of smallpox. Antiviral Res. 94(1) , 44–53 (2012).
  • Smee DF , GowenBB, WanderseeMK et al. Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment. Int. J. Antimicrob. Agents 31(4) , 352–359 (2008).
  • Parker S , SiddiquiAM, OberleC et al. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Virology 385(1) , 11–21 (2009).
  • Luker KE , LukerGD. Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation. Antiviral Res.78(3) , 179–187 (2008).
  • Zaitseva M , KapnickSM, ScottJ et al. Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. J. Virol. 83(20) , 10437–10447 (2009).
  • Americo JL , MossB, EarlPL. Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J. Virol.84(16) , 8172–8180 (2010).
  • Earl PL , AmericoJL, MossB. Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response. J. Virol.86(17) , 9105–9112 (2012).
  • Stabenow J , BullerRM, SchriewerJ, WestC, SagartzJE, ParkerS. A mouse model of lethal infection for evaluating prophylactics and therapeutics against monkeypox virus. J. Virol.84(8) , 3909–3920 (2010).
  • Schultz DA , SagartzJE, HusoDL, BullerRM. Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virus. Virology383(1) , 86–92 (2009).
  • Hutson CL , OlsonVA, CarrollDS et al. A prairie dog animal model of systemic orthopoxvirus disease using west African and Congo basin strains of monkeypox virus. J. Gen. Virol. 90(Pt 2) , 323–333 (2009).
  • Kramski M , Matz-RensingK, Stahl-HennigC et al. A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection. PLoS ONE 5(4) , e10412 (2010).
  • Israely T , ParanN, LustigS et al. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease. Virol. J. 9 , 119 (2012).
  • Verreault D , SivasubramaniSK, TaltonJD et al. Evaluation of inhaled cidofovir as postexposure prophylactic in an aerosol rabbitpox model. Antiviral Res. 93(1) , 204–208 (2012).
  • Parker S , SchriewerJ, OberleC et al. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. Antivir. Ther. 13(7) , 863–873 (2008).
  • Parker S , TouchetteE, OberleC et al. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res. 77(1) , 39–49 (2008).
  • Rice AD , AdamsMM, LampertB et al. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 3(2) , 63–82 (2011).
  • Rice AD , AdamsMM, WallaceG et al. Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 3(1) , 47–62 (2011).
  • Huggins J , GoffA, HensleyL et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53(6) , 2620–2625 (2009).
  • Smith SK , SelfJ, WeissS et al. Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox. J. Virol. 85(17) , 9176–9187 (2011).
  • Nalca A , HatkinJM, GarzaNL et al. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res. 79(2) , 121–127 (2008).
  • Berhanu A , KingDS, MosierS et al. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob. Agents Chemother. 53(12) , 4999–5009 (2009).
  • Grosenbach DW , BerhanuA, KingDS et al. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc. Natl Acad. Sci. USA 107(2) , 838–843 (2010).
  • Santos-Fernandes E , BeltrameCO, ByrdCM et al. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®. Antiviral Res. 97(3) , 301–311 (2013).
  • Howell MD , StreibJE, KimBE et al. Ceragenins: a class of antiviral compounds to treat orthopox infections. J. Invest. Dermatol. 129(11) , 2668–2675 (2009).
  • Smee DF , BaileyKW, WongMH, TarbetEB. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances. Antivir. Chem. Chemother.21(5) , 201–208 (2011).
  • Gammon DB , SnoeckR, FitenP et al. Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J. Virol. 82(24) , 12520–12534 (2008).
  • Reeves PM , SmithSK, OlsonVA et al. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J. Virol. 85(1) , 21–31 (2011).
  • Tarbet EB , LarsonD, AndersonBJ, BaileyKW, WongMH, SmeeDF. Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice. Antiviral Res.90(3) , 126–133 (2011).
  • Smee DF , WongMH, RussellA, EnnisJ, TurnerJD. Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201). PLoS ONE6(10) , e26330 (2011).
  • Altmann SE , SmithAL, DyallJ et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 93(2) , 305–308 (2012).
  • Ahmed CM , DabelicR, WaibociLW, JagerLD, HeronLL, JohnsonHM. SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system. J. Virol.83(3) , 1402–1415 (2009).
  • Chen N , BelloneCJ, SchriewerJ et al. Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy. Virology 409(2) , 328–337 (2011).
  • Bolken TC , HrubyDE. Discovery and development of antiviral drugs for biodefense: experience of a small biotechnology company. Antiviral Res.77(1) , 1–5 (2008).
  • Hostetler KY . Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res.82(2) , A84–A98 (2009).
  • De Clercq E . Historical perspectives in the development of antiviral agents against poxviruses. Viruses2(6) , 1322–1339 (2010).
  • Hostetler KY . Synthesis and early development of hexadecyloxypropyl cidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses2(10) , 2213–2225 (2010).
  • Quenelle DC , KernER. Treatment of vaccinia and cowpox virus infections in mice with CMX001 and ST-246. Viruses2(12) , 2681–2695 (2010).
  • Roy CJ , VossTG. Use of the aerosol rabbitpox virus model for evaluation of anti-poxvirus agents. Viruses2(9) , 2096–2107 (2010).
  • Nalca A , NicholsDK. Rabbitpox: a model of airborne transmission of smallpox. J. Gen. Virol.92(Pt 1) , 31–35 (2011).
  • Prichard MN , KernER. Orthopoxvirus targets for the development of new antiviral agents. Antiviral Res.94(2) , 111–125 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.